"New" Augmentin
Executive Summary
GSK expects approval in 2001 for both the sustained-release formulation of amoxicillin/clavulanate in a 16:1 concentration and the pediatric "extra strength" 14:1 formulation, Senior VP-New Product Development Palmer says. The NDA for Augmentin SR was filed in late December, while Augmentin ES was filed in 1997 and was reviewed by an FDA advisory committee in January (1"The Pink Sheet" Feb. 5, p. 6)
You may also be interested in...
Augmentin ES-600 Label Places Limit On Use For Penicillin-Resistant Strains
GlaxoSmithKline's Augmentin ES-600 labeling for otitis media sets a limit on the S. pneumoniae penicillin-resistant strains the antibiotic is expected to effectively treat.
Augmentin ES-600 Label Places Limit On Use For Penicillin-Resistant Strains
GlaxoSmithKline's Augmentin ES-600 labeling for otitis media sets a limit on the S. pneumoniae penicillin-resistant strains the antibiotic is expected to effectively treat.
GSK Augmentin ES Needs "Boundary" On Resistant Strains Covered, FDA Cmte
GlaxoSmithKline should indicate an upper "boundary" of penicillin resistance that its antibiotic Augmentin ES is expected to effectively treat, FDA's Anti-Infective Drugs Advisory Committee suggested Jan. 30.